We have shown that particularly in luminal A BC (ER+/HER2− tumors), RANK mediates an aggressive tumor phenotype, with decreased proliferation rate and susceptibility to chemotherapy and ET [206]. This evidence concerns the gene ESR1 and breast cancer.